2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2526

Perinatal Patterns of Medication Use in Women with Rheumatoid Arthritis: A Population-Based Study

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

9:00AM-11:00AM: Abstract Number: 2268

Peripheral Joint MRI for Inflammatory Arthritis and the Choosing Wisely Campaign – Evidence for Wide Variations in Use

Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

9:00AM-11:00AM: Abstract Number: 2669

Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2731

Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2928

Persistent Disease Activity over Time in a Large Canadian Cohort of Prevalent Lupus Patients

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2459

Personal and Environmental Factors Associated with Leisure Participation Among Children and Adolescents with Juvenile Idiopathic Arthritis

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ARHP): Pediatrics

9:00AM-11:00AM: Abstract Number: 2416

Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2873

Pharmacological Treatment of Psoriatic Arthritis (PSA): Systematic Literature Review for the Update of the EULAR Recommendations for the Management of PSA

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2697

Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2900

Phospholipase A2 Receptor 1 Antibody in Membranous Lupus Nephritis

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2457

Physical Function and Psychological Well-Being in Teens with Juvenile Idiopathic Arthritis (JIA): Characterization and Exploration of Technology-Assisted Self-Management

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ARHP): Pediatrics

9:00AM-11:00AM: Abstract Number: 2681

Physical Function, Sleep, Depression but Not CRP Level Is Associated with Fatigue in Patients with Established Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2272

Physical Performance Contributes Only Marginally in Explaining Fatigue Variation in Persons with RA Moderately Affected By Their Disease

Epidemiology and Public Health Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 3033

Polyarteritis Nodosa and Cutaneous Arteritis: Are They Distinct Diseases?

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 2300

Polymorphisms of Transient Receptor Potential Vanilloid (TRPV) 2 and TRPV3 Gene Polymorphisms Were Associated with Fibromyalgia in a Korean Population

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].